Ajeganova S, van Steenbergen HW, van Nies JA, Burgers LE, Huizinga TW, van der Helm-van Mil AH. Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms. Ann Rheum Dis 2016;75(5):867-73. https://www.ncbi.nlm.nih.gov/pubmed/25972519
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69(9):1580-8. https://www.ncbi.nlm.nih.gov/pubmed/20699241
Australia & New Zealand Musculoskeletal Clinical Trials Network (ANZMUSC). An Australian Living Guideline for the Pharmacological Management of Inflammatory Arthritis [version 2.8]. 2023; Accessed March 2023. https://app.magicapp.org/#/guideline/LqRV3n
Australia & New Zealand Musculoskeletal Clinical Trials Network (ANZMUSC). Initial DMARD therapy for people with rheumatoid arthritis. An Australian Living Guideline for the Pharmacological Management of Inflammatory Arthritis [version 28]. 2023; Accessed March 2023. https://app.magicapp.org/#/guideline/6936/section/121610
Australia & New Zealand Musculoskeletal Clinical Trials Network (ANZMUSC). Opioids for pain in rheumatoid arthritis. An Australian Living Guideline for the Pharmacological Management of Inflammatory Arthritis [version 28]. 2023; Updated November 2022. Accessed March 2023. https://app.magicapp.org/#/guideline/6936/section/121614
Australia & New Zealand Musculoskeletal Clinical Trials Network (ANZMUSC). Perioperative use of DMARDs in people with inflammatory arthritis. An Australian Living Guideline for the Pharmacological Management of Inflammatory Arthritis [version 28]. 2023; Updated October 2022. Accessed March 2023. https://app.magicapp.org/#/guideline/6936/section/121613
Australia & New Zealand Musculoskeletal Clinical Trials Network (ANZMUSC). Rheumatoid arthritis: Dose reduction or discontinuation of bDMARDs and tsDMARDs. An Australian Living Guideline for the Pharmacological Management of Inflammatory Arthritis [version 28]. 2023; Updated August 2022. Accessed March 2023. https://app.magicapp.org/#/guideline/6936/section/121607
Australia & New Zealand Musculoskeletal Clinical Trials Network (ANZMUSC). Subcutaneous/intramuscular methotrexate versus oral methotrexate for people with rheumatoid arthritis. An Australian Living Guideline for the Pharmacological Management of Inflammatory Arthritis [version 28]. 2023; Accessed March 2023. https://app.magicapp.org/#/guideline/6936/section/121611
Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Annals of the Rheumatic Diseases 2007;66 Suppl 3(Suppl 3):iii56-60. https://www.ncbi.nlm.nih.gov/pubmed/17934098
Blumenauer B, Judd M, Wells G, Burls A, Cranney A, Hochberg M, et al. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Review 2002;2002(3):CD003785. https://www.ncbi.nlm.nih.gov/pubmed/12137712
Criswell LA, Saag KG, Sems KM, Welch V, Shea B, Wells G, et al. Moderate-term, low-dose corticosteroids for rheumatoid arthritis. Cochrane Database of Systematic Review 2000;1998(2):CD001158. https://www.ncbi.nlm.nih.gov/pubmed/10796420
Escalas C, Dalichampt M, Combe B, Fautrel B, Guillemin F, Durieux P, et al. Effect of adherence to European treatment recommendations on early arthritis outcome: data from the ESPOIR cohort. Annals of the Rheumatic Diseases 2012;71(11):1803-8. https://www.ncbi.nlm.nih.gov/pubmed/22563026
Gøtzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev 2004;2005(3):CD000189. https://www.ncbi.nlm.nih.gov/pubmed/15266426
Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe DJ, Bombardier C. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. Cochrane Database of Systematic Review 2016;2016(8):CD010227. https://www.ncbi.nlm.nih.gov/pubmed/27571502
Ho Lee Y, Gyu Song G. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis. Journal of Clinical Pharmacy and Therapeutics 2020;45(4):674-81. https://www.ncbi.nlm.nih.gov/pubmed/32495356
Jacobs JW. The CAMERA (Computer-Assisted Management in Early Rheumatoid Arthritis) studies. Clin Exp Rheumatol 2012;30(4 Suppl 73):S39-43. https://www.ncbi.nlm.nih.gov/pubmed/23078796
Katchamart W, Bombardier C. Systematic monitoring of disease activity using an outcome measure improves outcomes in rheumatoid arthritis. J Rheumatol 2010;37(7):1411-5. https://www.ncbi.nlm.nih.gov/pubmed/20436069
Lethaby A, Lopez-Olivo MA, Maxwell L, Burls A, Tugwell P, Wells GA. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Review 2013;(5):CD004525. https://www.ncbi.nlm.nih.gov/pubmed/23728649
Lopez-Olivo MA, Amezaga Urruela M, McGahan L, Pollono EN, Suarez-Almazor ME. Rituximab for rheumatoid arthritis. Cochrane Database of Systematic Review 2015;1:CD007356. https://www.ncbi.nlm.nih.gov/pubmed/25603545
MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000;43(1):30-7. https://www.ncbi.nlm.nih.gov/pubmed/10643697
Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum 2010;62(6):1576-82. https://www.ncbi.nlm.nih.gov/pubmed/20191579
Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. Journal of Rheumatology 2006;33(6):1075-81. https://www.ncbi.nlm.nih.gov/pubmed/16652437
Nikiphorou E, Norton SJ, Carpenter L, Walsh DA, Creamer P, Dixey J, et al. Remission vs low disease activity: function, quality of life and structural outcomes in the Early Rheumatoid Arthritis Study and Network. Rheumatology (Oxford) 2020;59(6):1272-80. https://www.ncbi.nlm.nih.gov/pubmed/31580448
Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. Journal of Rheumatology 2003;30(6):1182-90. https://www.ncbi.nlm.nih.gov/pubmed/12784387
Ruiz Garcia V, Burls A, Cabello JB, Vela Casasempere P, Bort-Marti S, Bernal JA. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database of Systematic Review 2017;9(9):CD007649. https://www.ncbi.nlm.nih.gov/pubmed/28884785
Silman AJ, MacGregor AJ, Thomson W, Holligan S, Carthy D, Farhan A, et al. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br J Rheumatol 1993;32(10):903-7. https://www.ncbi.nlm.nih.gov/pubmed/8402000
Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. Journal of Rheumatology 2011;38(1):10-20. https://www.ncbi.nlm.nih.gov/pubmed/20952462
Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis: a systematic review. Journal of Rheumatology 2010;37(6):1096-104. https://www.ncbi.nlm.nih.gov/pubmed/20436075
Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases 2020;79(6):685-99. https://www.ncbi.nlm.nih.gov/pubmed/31969328
Studenic P, Aletaha D, de Wit M, Stamm TA, Alasti F, Lacaille D, et al. American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. Annals of the Rheumatic Diseases 2022;82(1):74-80. https://www.ncbi.nlm.nih.gov/pubmed/36280238
Suarez-Almazor ME, Belseck E, Shea B, Homik J, Wells G, Tugwell P. Antimalarials for treating rheumatoid arthritis. Cochrane Database of Systematic Review 2000;(4):CD000959. https://www.ncbi.nlm.nih.gov/pubmed/11034691
Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Sulfasalazine for rheumatoid arthritis. Cochrane Database of Systematic Review 2000;1998(2):CD000958. https://www.ncbi.nlm.nih.gov/pubmed/10796400
Yokogawa N, Shimada K, Sugii S, Komiya A, Matsui T, Nishino J, et al. A Proposal to Standardize Low Disease Activity Criteria in Rheumatoid Arthritis Based on the Outcome Measures in Rheumatology Minimal Disease Activity Definition. ACR Open Rheumatol 2020;2(5):301-6. https://www.ncbi.nlm.nih.gov/pubmed/32362072
